MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
1.110
+0.050
+4.72%
Opening 11:14 02/13 EST
OPEN
1.050
PREV CLOSE
1.060
HIGH
1.125
LOW
1.050
VOLUME
93.35K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.020
MARKET CAP
11.20M
P/E (TTM)
-0.3033
1D
5D
1M
3M
1Y
5Y
1D
Soligenix Provides Shareholder Update on Rare Disease Pipeline
TipRanks · 18h ago
Soligenix Inc. Publishes 2026 Shareholder Letter
Reuters · 19h ago
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX)
TipRanks · 1d ago
SOLIGENIX : CONTINUE TO EVALUATE POTENTIAL STRATEGIC OPTIONS, INCLUDING, BUT NOT LIMITED TO, PARTNERSHIP AND MERGER AND ACQUISITION OPPORTUNITIES
Reuters · 1d ago
Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma
Reuters · 1d ago
Soligenix Reports Progress on HyBryte Phase 3 Trial and Outlines 2026 Milestones
Reuters · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 4d ago
Weekly Report: what happened at SNGX last week (0202-0206)?
Weekly Report · 4d ago
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.